Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: DNLI

Denali Therapeutics Inc.

Healthcare | Biotechnology

No licensed closing price on file for DNLI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Denali Therapeutics Inc. (NASDAQ: DNLI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:00 UTC.

What Denali Therapeutics Inc. does

Denali is a biopharmaceutical company that has developed a proprietary technology called the TransportVehicle to enable delivery of large molecule medicines across the blood-brain barrier to treat serious diseases, particularly neurological and lysosomal storage disorders. The company is building a portfolio of therapeutic candidates across three franchise platforms: Enzyme TV, Oligonucleotide TV, and Antibody TV. Its most advanced program, tividenofusp alfa, is under FDA priority review for treating mucopolysaccharidosis II, with a target action date established.

Summarized from Denali Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-14.09%

Revenue, margins & earnings

FY2021: net loss $291M on revenue $49M$49MFY2021FY2022: net loss $326M on revenue $108M$108MFY2022FY2023: net loss $145M on revenue $331M$331MFY2023
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-09
  • 2026-09-09Chief Medical OfficerSale-1,654$36.9K
  • 2026-09-04DirectorSale-615$14.6K
  • 2026-09-04DirectorSale-10,824$247.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Denali Therapeutics Inc. do?

Denali is a biopharmaceutical company that has developed a proprietary technology called the TransportVehicle to enable delivery of large molecule medicines across the blood-brain barrier to treat serious diseases, particularly neurological and lysosomal storage disorders.

When did DNLI last file with the SEC?

Denali Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:00 UTC. This page is also available as JSON at /api/data?ticker=DNLI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DNLI and 5,000+ tickers.

Create a free account — keep DNLI
For your agent
GET /api/data?ticker=DNLI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt